CR1 (n = 72) | Non-CR1 (n = 8) | P value | |
---|---|---|---|
Age (years) | |||
< 5 years (n = 3) | 3 (4.2%) | 0 (0.0%) | 0.118 |
5–9.99 years (n = 23) | 23 (31.9%) | 0 (0.0%) | |
≥ 10 years (n = 54) | 46 (63.9%) | 8 (100.0%) | |
Gender | |||
Female (n = 35) | 32 (44.4%) | 3 (37.5%) | 0.707 |
Male (n = 45) | 40 (55.6%) | 5 (62.5%) | |
B symptoms | |||
No (n = 46) | 44 (61.1%) | 2 (25.0%) | 0.050* |
Yes (n = 34) | 28 (38.9%) | 6 (75.0%) | |
Primary site | |||
Peripheral lymph nodes (n = 65) | 58 (80.6%) | 7 (87.5%) | 0.286 |
Mediastinum (n = 15) | 14 (19.4%) | 1 (12.5%) | |
Bulky | |||
No (n = 59) | 52 (72.2%) | 7 (87.5%) | 0.351 |
Yes (n = 21) | 20 (27.8%) | 1 (12.5%) | |
Extra nodal involvement | |||
No (n = 51) | 48 (66.7%) | 3 (37.5%) | 0.104 |
Yes (n = 29) | 24 (33.3%) | 5 (62.5%) | |
Pathology | |||
cHL, nodular sclerosis (n = 44) | 39 (54.2%) | 5 (62.5%) | 0.395 |
cHL, mixed cellularity (n = 18) | 15 (20.8%) | 3 (37.5%) | |
cHL, lymphocyte rich (n = 9) | 9 (12.5%) | 0 (0.0%) | |
NLPHL (n = 9) | 9 (12.5%) | 0 (0.0%) | |
Stage | |||
Early (I, II) (n = 30) | 30 (41.7%) | 0 (0.0%) | 0.022* |
Advanced (III, IV) (n = 50) | 42 (58.3%) | 8 (100.0%) | |
Risk group | |||
Low (n = 12) | 12 (16.7%) | 0 (0.0%) | 0.012* |
Intermediate (n = 44) | 42 (58.3%) | 2 (25.0%) | |
High (n = 24) | 18 (25.0%) | 6 (75.0%) |